Prognostic Risk Stratification in Acute GVHD

Abstract

 Acute graft-versus-host disease (GVHD) remains a major complication after allogeneic hematopoietic cell transplantation. Although advances in prophylactic strategies have reduced the incidence of severe GVHD, treatment resistance remains a significant concern. Even in patients who respond to systemic corticosteroids, adverse events such as GVHD recurrence and steroid-related complications, including infections and primary disease relapse, are common. Some patients may be overtreated or undertreated, highlighting the need for personalized treatment approaches based on individual risk. Risk stratification using clinical symptoms and biomarkers has been proposed, and the Mount Sinai Acute GVHD International Consortium (MAGIC) has developed an integrated model that combines both. Clinical trials using such models to guide individualized GVHD treatment are expected to improve patient outcomes.